Evolent Health (NYSE:EVH) Releases Earnings Results, Misses Expectations By $0.35 EPS

Evolent Health (NYSE:EVH) issued its quarterly earnings data on Thursday. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35), Zacks reports. Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. The firm had revenue of $646.54 million during the quarter, compared to analysts’ expectations of $650.92 million. Evolent Health updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Evolent Health Stock Performance

Shares of Evolent Health stock traded up $0.27 during trading on Friday, hitting $10.98. 1,678,306 shares of the company’s stock were exchanged, compared to its average volume of 2,133,135. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -12.05 and a beta of 1.45. The business has a 50-day simple moving average of $10.77 and a 200-day simple moving average of $18.92. Evolent Health has a 52-week low of $9.45 and a 52-week high of $35.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Analyst Ratings Changes

Several research firms have issued reports on EVH. UBS Group cut their price target on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. Truist Financial dropped their target price on Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Stephens decreased their price target on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. Citigroup dropped their price target on Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Oppenheimer cut their price objective on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Evolent Health has a consensus rating of “Buy” and an average price target of $17.79.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.